SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 218 filers reported holding SAGE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.64 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $62,337 | -54.1% | 3,029 | +4.8% | 0.00% | -57.1% |
Q2 2023 | $135,935 | +12.1% | 2,891 | 0.0% | 0.01% | +16.7% |
Q1 2023 | $121,306 | +1.0% | 2,891 | -8.2% | 0.01% | +20.0% |
Q4 2022 | $120,065 | -2.6% | 3,148 | 0.0% | 0.01% | -16.7% |
Q3 2022 | $123,276 | +21.2% | 3,148 | 0.0% | 0.01% | +50.0% |
Q2 2022 | $101,680 | +133.4% | 3,148 | +207.4% | 0.00% | +300.0% |
Q4 2021 | $43,561 | -3.7% | 1,024 | +0.3% | 0.00% | 0.0% |
Q3 2021 | $45,241 | -25.0% | 1,021 | -3.9% | 0.00% | 0.0% |
Q2 2021 | $60,332 | -34.7% | 1,062 | -13.9% | 0.00% | 0.0% |
Q1 2021 | $92,365 | -11.7% | 1,234 | +2.1% | 0.00% | -50.0% |
Q4 2020 | $104,591 | +37.6% | 1,209 | -2.8% | 0.00% | +100.0% |
Q3 2020 | $76,033 | +44.7% | 1,244 | -1.6% | 0.00% | 0.0% |
Q2 2020 | $52,557 | -48.9% | 1,264 | -64.7% | 0.00% | -50.0% |
Q1 2020 | $102,875 | -61.4% | 3,582 | -3.1% | 0.00% | -50.0% |
Q4 2019 | $266,742 | -48.8% | 3,695 | -0.5% | 0.00% | -55.6% |
Q3 2019 | $521,177 | -20.6% | 3,715 | +3.6% | 0.01% | -18.2% |
Q2 2019 | $656,744 | +12.5% | 3,587 | -2.3% | 0.01% | 0.0% |
Q1 2019 | $583,714 | +74.3% | 3,670 | +5.0% | 0.01% | +57.1% |
Q4 2018 | $334,882 | -32.4% | 3,496 | -0.3% | 0.01% | -22.2% |
Q3 2018 | $495,505 | -99.9% | 3,508 | -1.9% | 0.01% | 0.0% |
Q2 2018 | $559,908,000 | -73.4% | 3,577 | -72.6% | 0.01% | -70.0% |
Q1 2018 | $2,104,541,000 | +108605.6% | 13,066 | +11.2% | 0.03% | +15.4% |
Q4 2017 | $1,936,000 | +32.5% | 11,752 | -49.9% | 0.03% | +188.9% |
Q3 2017 | $1,461,000 | -21.8% | 23,452 | 0.0% | 0.01% | -30.8% |
Q2 2017 | $1,868,000 | +23.1% | 23,452 | +9.9% | 0.01% | +18.2% |
Q1 2017 | $1,517,000 | +39.2% | 21,340 | 0.0% | 0.01% | +37.5% |
Q4 2016 | $1,090,000 | +20.0% | 21,340 | +8.2% | 0.01% | +14.3% |
Q3 2016 | $908,000 | +52.9% | 19,722 | 0.0% | 0.01% | +75.0% |
Q2 2016 | $594,000 | +53.5% | 19,722 | +63.3% | 0.00% | +33.3% |
Q1 2016 | $387,000 | -31.9% | 12,077 | +24.0% | 0.00% | -25.0% |
Q4 2015 | $568,000 | +37.9% | 9,742 | 0.0% | 0.00% | +33.3% |
Q3 2015 | $412,000 | -42.1% | 9,742 | 0.0% | 0.00% | -40.0% |
Q2 2015 | $711,000 | +315.8% | 9,742 | +108.7% | 0.01% | +400.0% |
Q4 2014 | $171,000 | -34.5% | 4,668 | -43.6% | 0.00% | -50.0% |
Q3 2014 | $261,000 | – | 8,277 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
RA Capital Management | 350,933 | $49,569,000 | 2.65% |
Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |